Oropharyngeal Cancers

3

Review clinical trials related to Oropharyngeal Cancers. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Enhancing Oral Cancer Awareness

To evaluate the impact of AI-powered chatbot interactions versus traditional educational handouts on increasing participants' knowledge of oral cancer and its prevention

Participants needed: 60
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Virginia Commonwealth UniversityUpdated: May 8, 2026Locations: 1
Eligibility criteria

Identify as African American as defined by the US Census [+1]

Individuals who cannot physically or mentally participate in the research projec... [+3]

Status: Recruiting

Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy

The current standard treatment option for Human Papillomavirus (HPV) or p16-positive oropharyngeal cancer is full-dose radiation combined with chemotherapy. Results with chemotherapy combined with full-dose radiation therapy leads to high rates of cure; this has called into question whether therapy can be decreased in intensity since both chemotherapy and radiation have long-term side effects. One approach to decrease intensity of treatment is to give radiation alone (excluding chemotherapy) and to decrease radiation therapy dose. The investigator believes that omitting chemotherapy and decreasing radiation dose both to tumor and the regions of the head and neck at highest risk of potential spread, may have no significant impact on the cancer recurring while potentially leading to fewer long-term side effects.

Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Georgetown UniversityUpdated: Apr 17, 2026Locations: 2
Eligibility criteria

Patients must be ≥ 18 years of age on the day of signing informed consent. [+9]

Patients with gross involvement of level 4 lymph node level [+5]

Status: Not yet recruiting

SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer

Oropharyngeal cancer (OPC) is the most common type of head and neck cancer. The current standard treatment for this cancer is radiotherapy (RT) of the tumour and lymph nodes of both sides of the neck, combined with concurrent chemotherapy for advanced stages. Even though a small proportion of patients with this cancer have involvement of the lymph nodes of the neck on the opposite side of the tumour (contralateral involvement) or involvement of the lymph nodes on both sides of the neck (bilateral involvement), bilateral radiotherapy is performed due to the risk of contralateral microscopic involvement, which is invisible on imaging and clinical examination. Bilateral radiotherapy causes more adverse events, leading to a decrease in quality of life. Lymphatic mapping using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging is a technique that visualises the lymphatic drainage of the tumour and thus determines whether radiotherapy should be delivered unilaterally or bilaterally to the lymph nodes. This technique would therefore reduce adverse events and improve quality of life, while maintaining the efficacy of radiotherapy. The goal of the clinical trial SELECT-FR is to investigate if the efficacy of a lymphatic drainage mapping with a SPECT-CT-guided approach is acceptable in terms of two-year Disease Free Survival (DFS) rate in patients with lateralized OPC.

Participants needed: 128
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: UNICANCERUpdated: Mar 24, 2026Locations: 12
Eligibility criteria

Patients must have signed a written informed consent form prior to any trial spe... [+16]

Patients with T1-T2 cancers isolated to the tonsil fossa (i.e., without any soft... [+13]